• / Free eNewsletters & Magazine
  • / My Account
Home>Finance>Food>Food And Drug Administration

Food And Drug Administration

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Icon Bioscience Annouces FDA Acceptance of NDA Filing for DEXYCU, a Noval Drug Therapy for Treating Inflammation Associated with Cataract Surgery

    Icon Bioscience Annouces FDA Acceptance of NDA Filing for DEXYCU, a Noval Drug Therapy for Treating Inflammation Associated with Cataract Surgery

  2. FDA Approves RITUXAN HYCELA (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers

    FDA Approves RITUXAN HYCELA (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers

  3. Synlogic Receives Fast Track Designation in U.S. for Lead Candidate, SYNB1020

    Synlogic Receives Fast Track Designation in U.S. for Lead Candidate, SYNB1020

  4. Alnylam Reports New Positive Clinical Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias

    Alnylam Reports New Positive Clinical Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias

  5. UPDATE: This is how much lead was found in random baby food samples

    UPDATE: This is how much lead was found in random baby food samples

  6. Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

    Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

  7. Four-Year Follow-up with Empliciti (elotuzumab) Plus Lenalidomide/Dexamethasone (ELd) in Patients with Advanced Multiple Myeloma Shows Long-term Efficacy in ELOQUENT-2 Trial

    Four-Year Follow-up with Empliciti (elotuzumab) Plus Lenalidomide/Dexamethasone (ELd) in Patients with Advanced Multiple Myeloma Shows Long-term Efficacy in ELOQUENT-2 Trial

  8. Portola Pharma stock skyrockets after FDA approves anticoagulant for high-risk patients

    Portola Pharma stock skyrockets after FDA approves anticoagulant for high-risk patients

  9. FDA Chief Sidesteps Questions About Trump's Proposed Agency Budget Overhaul

    FDA Chief Sidesteps Questions About Trump's Proposed Agency Budget Overhaul

  10. FDA Chief Sidesteps Questions About Trump's Proposed Agency Budget Overhaul -- Update

    FDA Chief Sidesteps Questions About Trump's Proposed Agency Budget Overhaul -- Update

12345

©2017 Morningstar Advisor. All right reserved.